GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenerx Biopharmaceuticals Inc (OTCPK:RGRX) » Definitions » Shiller PE Ratio

Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Regenerx Biopharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regenerx Biopharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Regenerx Biopharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenerx Biopharmaceuticals Shiller PE Ratio Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regenerx Biopharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenerx Biopharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regenerx Biopharmaceuticals's Shiller PE Ratio falls into.



Regenerx Biopharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regenerx Biopharmaceuticals's E10 for the quarter that ended in Mar. 2023 is calculated as:

For example, Regenerx Biopharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.268/127.3478*127.3478
=-0.268

Current CPI (Mar. 2023) = 127.3478.

Regenerx Biopharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201306 0.000 98.518 0.000
201309 0.000 98.790 0.000
201312 0.000 98.326 0.000
201403 -3.000 99.695 -3.832
201406 -0.235 100.560 -0.298
201409 0.115 100.428 0.146
201412 -1.000 99.070 -1.285
201503 -2.000 99.621 -2.557
201506 -2.000 100.684 -2.530
201509 -1.000 100.392 -1.269
201512 0.000 99.792 0.000
201603 -3.000 100.470 -3.803
201606 2.000 101.688 2.505
201609 1.000 101.861 1.250
201612 0.395 101.863 0.494
201703 0.087 102.862 0.108
201706 0.094 103.349 0.116
201709 -1.000 104.136 -1.223
201712 1.237 104.011 1.515
201803 -1.000 105.290 -1.210
201806 -0.307 106.317 -0.368
201809 -0.306 106.507 -0.366
201812 -1.000 105.998 -1.201
201903 -0.320 107.251 -0.380
201906 -0.296 108.070 -0.349
201909 -0.254 108.329 -0.299
201912 0.000 108.420 0.000
202003 -0.291 108.902 -0.340
202006 -0.327 108.767 -0.383
202009 -0.249 109.815 -0.289
202012 0.000 109.897 0.000
202103 -0.284 111.754 -0.324
202106 -0.253 114.631 -0.281
202109 -0.300 115.734 -0.330
202112 0.000 117.630 0.000
202203 -0.295 121.301 -0.310
202206 -0.380 125.017 -0.387
202209 -0.255 125.227 -0.259
202212 0.000 125.222 0.000
202303 -0.268 127.348 -0.268

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regenerx Biopharmaceuticals  (OTCPK:RGRX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Regenerx Biopharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Regenerx Biopharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Executives
Aptafin S P A other: Member of 10% owner group VIALE SHAKESPEARE 47, ROME L6 00144
Alessandro Noseda director C/O 15245 SHADY GROVE ROAD, SUITE 470, ROCKVILLE MD 20850
S.a. Sinaf 10 percent owner 26 BOULEVARD ROYAL, LUXEMBOURG N4 L-2449
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Francesca Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Silvia Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Preta Martina Cavazza 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Mauro Bove director C/O REGENERX BIOPHARMACEUTICALS, INC., 3 BETHESDA METRO CENTER - SUITE 630, BETHESDA MD 20814
R Don Elsey director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
J J Finkelstein director
Joseph C Mcnay director 3 BETHESDA METRO CENTER STE 700, C/O REGENERX BIOPHARMACEUTICALS INC, BETHESDA MD 20814
Allan L Goldstein director
Dane R Saglio officer: Chief Financial Officer
Aria Digital 10 percent owner 22ND FL, PARKVIEW TOWER,, 248 JUNGJAIL-RO, BUNDANG-GU,, SEONGNAM-SI, GYEONGGI-DO M4 463-863

Regenerx Biopharmaceuticals (Regenerx Biopharmaceuticals) Headlines